Apontis Pharma AG
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
APONTIS PHARMA AG is a leading pharmaceutical company in Germany that specialises in single pills. Single Pills combine two to three generic active ingredients in one combination preparation. APONTIS PHARMA develops, markets and distributes a broad portfolio of Single Pills and other medicines, with a particular focus on cardiovascular diseases. Since 2013, APONTIS has successfully launched several Single Pills solely for cardiovascular indications such as hypertension, hyperlipidaemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in the heart of Europe's strongest pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a target customer group of around 23,000 doctors in Germany.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-13 10:30 |
Major Shareholding Notification
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
|
English | 7.2 KB | |
| 2025-05-15 07:30 |
Earnings Release
APONTIS PHARMA publishes results for the first quarter of 2025 and confirms for…
|
English | 25.5 KB | |
| 2025-03-31 14:00 |
Earnings Release
APONTIS PHARMA with significant sales and earnings increase in 2024 financial y…
|
English | 26.3 KB | |
| 2025-03-31 00:00 |
Annual Report
Annual financial statements 2024
|
English | 1.3 MB | |
| 2025-03-06 20:50 |
Major Shareholding Notification
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
|
English | 7.6 KB | |
| 2025-03-05 20:50 |
Major Shareholding Notification
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
|
English | 7.6 KB | |
| 2024-12-12 14:42 |
Directors' Dealings
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
|
English | 7.7 KB | |
| 2024-12-11 16:00 |
Directors' Dealings
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
|
English | 7.7 KB | |
| 2024-12-10 10:35 |
Directors' Dealings
APONTIS PHARMA AG: Thomas Zimmermann, sell
|
English | 7.5 KB | |
| 2024-11-22 11:30 |
Takeover Announcement Report
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
|
English | 14.2 KB | |
| 2024-11-21 11:30 |
Takeover Announcement Report
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
|
English | 14.2 KB | |
| 2024-11-07 07:30 |
Earnings Release
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations i…
|
English | 40.7 KB | |
| 2024-10-30 16:20 |
Takeover Announcement Report
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting…
|
English | 13.9 KB | |
| 2024-10-16 11:55 |
Takeover Announcement Report
APONTIS PHARMA and Zentiva entered into partnership for future growth Zentiva …
|
English | 17.1 KB | |
| 2024-10-16 11:50 |
Takeover Announcement Report
APONTIS PHARMA and Zentiva enter into investment agreement Zentiva will launch…
|
English | 9.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Adocia | France | ADOC | |
|
Advicenne | France | ALDVI | |
|
Aelis Farma | France | AELIS | |
|
Aker BioMarine | Norway | AKBM | |
|
ALK-Abelló | Denmark | ALK | |
|
Alligator Bioscience | Sweden | ATORX | |
|
Alvotech Holdings S.A | Luxembourg | ALVO | |
|
AlzeCure Pharma | Sweden | ALZCUR | |
|
Alzinova AB | Sweden | ALZ | |
| Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS | Türkiye | ANGEN |